The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials

BMC Psychiatry

Table 4 MMRM and LOCF_ANCOVA analysis of three focus outcomes from duloxetine clinical trials.

	Study 1		Study 2		Study 3		Study 4		Study 5				Study 6				Study 7				Study 8
Dose	60 mg QD		60 mg QD		60 mg BID		60 mg BID		20 mg BID		40 mg BID		20 mg BID		40 mg BID		40 mg BID		60 mg BID		40 mg BID		60 mg BID
	Δ	p	Δ	p	Δ	p	Δ	p	Δ	p	Δ	p	Δ	p	Δ	p	Δ	p	Δ	p	Δ	p	Δ	p
HAMD ₁₇ Total Score
MMRM	4.9	< .001	2.2	.024	3.1	.009	0.9	.415	1.4	.143	1.5	.116	2.4	.034	3.6	.002	2.2	.001	3.3	< .001	1.4	.045	1.6	.014
LOCF	3.8	< .001	1.7	.048	2.1	.066	0.4	.681	1.2	.222	1.5	.138	2.4	.022	3.1	.003	2.2	.007	3.0	< .001	0.9	.253	1.5	.054
HAMD ₁₇ Maier Subscale
MMRM	2.8	< .001	1.6	.003	2.0	.005	0.7	.282	1.2	.037	1.4	.012	1.1	.068	1.7	.005	1.4	< .001	2.0	< .001	0.9	.022	1.2	.002
LOCF	2.3	< .001	1.4	.007	1.0	.030	0.6	.481	1.0	.058	1.3	.012	1.5	.028	1.8	.004	1.4	.001	1.9	< .001	0.7	.090	1.0	.014
VAS Overall Pain Severity
MMRM	5.9	.055	4.4	.135	NA		NA		0.3	.931	1.2	.731	1.0	.771	7.4	.035	5.5	.085	6.3	.050	5.6	.044	1.3	.625
LOCF	6.9	.019	5.2	.037	NA		NA		3.5	.573	3.5	.647	3.2	.710	7.1	.048	6.1	.063	5.6	.086	7.8	.014	5.5	.066

ISSN: 1471-244X